VALENTINA STERLIN: Open Payments
NPI 1932561008 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,995 in 134 payments from 30 companies in 2025. Trend: 2023 $3,659 · 2024 $2,818 · 2025 $7,995
Food & beverage: $2,545Speaker / faculty: $2,200Travel & lodging: $1,883Long term medical supply or device loan: $1,098Education: $269
| Company | Payments | Amount |
|---|---|---|
| Stemline Therapeutics Inc. | 8 | $4,232 |
| Novartis Pharmaceuticals Corporation | 35 | $1,484 |
| Janssen Biotech, Inc. | 17 | $440 |
| E.R. Squibb & Sons, L.L.C. | 12 | $229 |
| AstraZeneca Pharmaceuticals LP | 6 | $226 |
| Gilead Sciences, Inc. | 5 | $188 |
| SOBI, INC | 6 | $167 |
| BeOne Medicines USA, Inc. | 4 | $103 |
| GlaxoSmithKline, LLC. | 3 | $80 |
| PharmaEssentia USA Corporation | 4 | $79 |
Products named: Orserdu, KISQALI, Trodelvy, RYBREVANT, DARZALEX, LUTATHERA, REBLOZYL, BRUKINSA.
Industry payments across NY — which companies pay providers there.
